| 发明名称 |
TRANSDERMAL FORMULATION |
| 摘要 |
The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-¢4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo-¢2.2.2!octane transdermal formulation. The invention provides desired transdermal 3-¢4-(butylthio)-1,2,5-thiadiazol-3-yl!-1-azabicyclo¢2.2.2!octane patch formulations.
|
| 申请公布号 |
CA2212874(A1) |
申请公布日期 |
1996.08.22 |
| 申请号 |
CA19962212874 |
申请日期 |
1996.02.01 |
| 申请人 |
ELI LILLY AND COMPANY |
发明人 |
SHANNON, HARLAN EDGAR;BYMASTER, FRANKLIN PORTER;VALIA, KIRTI HIMATLAL;SHIPLEY, LISA ANN |
| 分类号 |
A61K9/70;A61K31/435;A61K31/439;A61K47/06;A61P25/04;A61P25/28;(IPC1-7):A61K31/445 |
主分类号 |
A61K9/70 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
|
| 地址 |
|
